142 results
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
and potential equity financing opportunities. The Company believes these sources will be sufficient to cover the known short and long-term requirements
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
hair fibers. The anticipated long-term result of RCH-01 injections is the restoration and maintenance of a patient's hair.
Phase I Clinical Trial … primary objective was to provide a long-term safety profile of injections of cultured DSC cells five years after injection compared to control
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
. The anticipated long-term result of RCH-01 injections is the restoration and maintenance of a patient's hair.
Phase I Clinical Trial (Europe)
The primary … was to provide a long-term safety profile of injections of cultured DSC cells five years after injection compared to control. This objective was met
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
and potential equity financing opportunities. The Company believes these sources will be sufficient to cover the known short and long-term requirements
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Aug 23
Notice of Annual General and Special Meeting of Shareholders
5:15pm
based company which provides independent pharmacies servicing long-term care and home care patients access to cost effective solutions. He … compensation strategy is to offer medium-term and long-term compensation components to ensure that the Company has in place programs to attract, retain
6-K
EX-99.1
gmg kkltiid
9 Aug 23
Statement of Executive Compensation
7:41pm
6-K
EX-99.2
ot5gut8 1hosne
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.1
o9v6cw nut5w7u
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.2
h8mw4 t8uz
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.1
gdemu6 9zo9j
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
20-F/A
j257yv
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.1
14rp2ztp enw37rw
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.2
9v1884y22o
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.3
dz7bk4 cf
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.4
qlo00 a3k
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.1
gdy whzpq
7 Jul 22
Statement of Executive Compensation
1:43pm
6-K
EX-99.1
d3h7x n0k
30 Jun 22
Statement of Executive Compensation
11:16am
6-K
EX-99.1
wucbv r1m
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm